Our aims were (i) to perform a complete characterization of the phenotypic spectrum of male obesity to identify novel markers of metabolic dysfunction, (ii) to explore the role of central inflammation in obesity-associated HH, and (iii) to investigate the contribution of FGF21 to the benefits of bariatric surgery. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.